Biogen not pursuing a sale: source

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/14/2026

1. DPZ
2. NVDA
3. BAC
4. DRS
5. GS
6. AVAV
7. ACI
8. UNH
9. ORCL
10. LQDA

Go back to Biogen not pursuing a sale: source

Mizuho Securities Cuts Price Target on Teva Pharma (TEVA) Following 2Q Beat

August 8, 2016 6:53 AM EDT

Mizuho Securities maintained a Buy rating on Teva Pharma (NYSE: TEVA), and cut the price target to $70.00 (from $75.00), following the company's 2Q earnings report. TEVA reported revenue of $5.0B and $1.25 EPS, vs. $4.88B and $1.20 consensus and management's recent guidance of $4.9- $5.0B and... More